| 1 |
NCT03830424 |
Not yet recruiting
New |
Assessment of Autonomic Nervous Regulation During Postnatal Period in Newborns |
|
- Procedure: Pain stimulus
- Dietary Supplement: Non-pharmacological pain relief
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Characteristics of parasympathetic (vagal) heart regulation in newborns in relation to nociception
- Characteristics of sympathetic activity in newborns in relation to nociception
- Autonomic (parasympathetic) reactivity in response to non-pharmacological pain relief in newborns
- (and 20 more...)
|
75 |
All |
up to 4 Days (Child) |
NCT03830424 |
EK69/2018 |
|
February 15, 2019 |
October 1, 2020 |
December 31, 2020 |
February 5, 2019 |
February 5, 2019 |
|
- Jessenius Medical Faculty, Comenius University
Martin, Slovakia
|
|
| 2 |
NCT03511924 |
Recruiting |
Intradialytic Resistance Training in Haemodialysis Patients |
- Chronic Kidney Disease Requiring Chronic Dialysis
|
- Behavioral: Intradialytic resistance training
|
Interventional
|
Not Applicable |
- Pavol Jozef Safarik University
- Dialysis Services Fresenius Medical Care Slovakia
- Private Health Institution Logman - Logman East
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in lower extremity muscle strength
- Change in activity of circulatory miRNA molecules involved in TRIM63 and IGF-1 signalling pathways
- Change in renal specific clinical data
- (and 2 more...)
|
50 |
All |
30 Years and older (Adult, Older Adult) |
NCT03511924 |
PJSU-JR |
IRTHEP |
January 11, 2018 |
June 30, 2019 |
December 31, 2019 |
April 30, 2018 |
February 12, 2019 |
|
- Fresenius Medical Care - Dialysis Services Košice, Slovakia
Košice, Slovakia
|
|
| 3 |
NCT03403777 |
Active, not recruiting |
Avelumab in Refractory Testicular Germ Cell Cancer. |
- Testicular Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms
- (and 4 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute, Slovakia
- Merck KGaA, Darmstadt, Germany
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the efficacy (as measured by 12-week progression-free survival) of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- To describe the favorable response rate of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Progression-free survival (PFS) of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Toxic effects of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
|
8 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03403777 |
NCISlovakia |
|
November 15, 2017 |
February 28, 2019 |
February 28, 2020 |
January 19, 2018 |
February 5, 2019 |
|
- National Cancer Institute
Bratislava, Slovakia
|
|
| 4 |
NCT03329053 |
Recruiting |
Utilization of Physical Activity Recommendations Among Patients of Cardiovascular Healthcare Centres in Eastern Slovakia |
|
- Behavioral: The EAPC Exercise Prescription (EXPERT) Tool
- Behavioral: Standard Cardio-Care Lifestyle Counselling
|
Interventional
|
Not Applicable |
- Pavol Jozef Safarik University
- University of Groningen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in exercise recommendations compliance at three months
- Change in body weight at three months
- Change in body height at three months
- (and 4 more...)
|
400 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT03329053 |
PJSU-1/0825/17 |
AWATAR |
February 23, 2018 |
December 2018 |
December 2018 |
November 1, 2017 |
March 7, 2018 |
|
- Cardiology and Internal Medicine Ambulance
Košice, Slovakia
|
|
| 5 |
NCT03282682 |
Recruiting |
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male |
- Hypogonadism, Male
- Physical Activity
- Testosterone Deficiency
|
- Procedure: Strength training
|
Interventional
|
Not Applicable |
- Comenius University
- Norwegian School of Sport Sciences
- Slovak Academy of Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Body composition - Change in Lean Mass at 12 weeks
- Body composition - Change in Fat Mass at 12 weeks
- Body composition - Change in Total Body Mass at 12 weeks
- (and 13 more...)
|
36 |
Male |
45 Years to 60 Years (Adult) |
NCT03282682 |
FSPORT-CU-ADAM |
|
October 1, 2017 |
October 31, 2018 |
December 31, 2018 |
September 14, 2017 |
August 14, 2018 |
|
- Comenius University in Bratislava, Faculty of physical education and sport
Bratislava, Slovakia
|
|
| 6 |
NCT03212131 |
Completed |
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. |
- Growth Hormone Disorder
- Adult Growth Hormone Deficiency
- Growth Hormone Deficiency in Children
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area under the somapacitan serum concentration time curve
- Maximum serum concentration of somapacitan
- Time to maximum serum concentration of somapacitan
- (and 2 more...)
|
34 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03212131 |
NN8640-4298
U1111-1187-9247
2016-003911-36 |
|
August 16, 2017 |
March 8, 2018 |
March 8, 2018 |
July 11, 2017 |
March 22, 2018 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 7 |
NCT03203096 |
Completed |
Magnesium Supplementation in Stress Conditions |
|
- Dietary Supplement: Magnesium
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Protina Pharmazeutische GmbH
- Comenius University
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- blood sampling
- 24h-urine
- heart rate variability
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03203096 |
StressMag2017 |
|
January 15, 2017 |
June 6, 2017 |
June 6, 2017 |
June 29, 2017 |
June 29, 2017 |
|
- Biomed Martin
Martin, Slovakia
|
|
| 8 |
NCT03105232 |
Recruiting |
Opioid-Redox Study |
|
|
Observational
|
|
- Pavol Jozef Safarik University
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Antioxidant enzymes
- Numerical pain scale
- Pain detetct score
|
300 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03105232 |
N28/11/16 |
ORS |
August 20, 2018 |
May 1, 2019 |
May 1, 2020 |
April 7, 2017 |
August 1, 2018 |
|
- 1st clinic of anesthesiology and intesive care, University hospital of Louis Pasteur
Košice, Slovakia
|
|
| 9 |
NCT03055559 |
Completed |
Trial Protocol GlobiFer - Oral Iron Repletion |
|
- Dietary Supplement: Globifer Forte
|
Observational
|
|
- Gedeon Richter Slovakia, s.r.o.
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Proportion of patients with a clinical relevant increase of the haemoglobin level treatment with GlobiFer Forte
|
60 |
Female |
18 Years to 60 Years (Adult) |
NCT03055559 |
Not identified |
TPG |
June 2016 |
May 4, 2017 |
May 4, 2017 |
February 16, 2017 |
March 14, 2018 |
|
- Prof. MUDr. Ján Danko, PhD.
Martin, Slovakia
|
|
| 10 |
NCT03052595 |
Recruiting |
Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance |
- Multiple Sclerosis
- Mitochondrial Alteration
|
- Diagnostic Test: Oral glucose tolerance test
- Diagnostic Test: Testing of autonomous nervous system function
- Diagnostic Test: Stroop test
|
Observational
|
|
- Slovak Academy of Sciences
- Comenius University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Insulin sensitivity
- Expanded Disability Status Scale (EDSS)
|
70 |
All |
18 Years to 45 Years (Adult) |
NCT03052595 |
APVV 15-0228 |
MS-MIDY |
February 1, 2017 |
June 30, 2020 |
December 31, 2021 |
February 14, 2017 |
December 13, 2018 |
|
- Biomedical Center, Slovak Academy of Sciences, Institute of clinical and translational reasearch
Bratislava, Slovakia
|
|
| 11 |
NCT03039296 |
Recruiting |
EuroPainClinics® Study IV (Prospective Observational Study) |
- Low Back Pain
- Facet Joint Pain
|
- Procedure: Endoscopic rhizotomy
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Pain as assessed by the Visual analogue scale
- Pain localization as assessed by note of radiating dermatome as neurologic examination
- Pain progress as assessed by global pain scale
- Changes in analgesics drugs consumption as assessed by equianalgesic dose ratios for opioids
|
150 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03039296 |
5N/2016 |
EPCSIV |
February 3, 2017 |
January 1, 2020 |
December 31, 2021 |
February 1, 2017 |
February 11, 2019 |
|
- Europainclinics
Košice, Slovakia
|
|
| 12 |
NCT02860819 |
Recruiting |
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer |
|
- Drug: Veliparib
- Drug: Gemcitabine
- Drug: Carboplatin
|
Interventional
|
Phase 2 |
- National Cancer Institute, Slovakia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients that will be free of disease progression according to RECIST criteria 12-months after the first administration of the treatment.
- Response rate
- Median overall survival
- (and 2 more...)
|
43 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02860819 |
GCTSK004 |
|
July 2016 |
December 2018 |
December 2018 |
August 9, 2016 |
August 22, 2018 |
|
- National Cancer Institute
Bratislava, Slovakia
|
|
| 13 |
NCT02837939 |
Recruiting |
Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction |
|
- Drug: Human derived Transfer factor
- Drug: Aqua pro injectione 4ml ampules for subcutaneous injection
|
Interventional
|
Phase 2
Phase 3 |
- Martin Janičko
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- Pavol Jozef Safarik University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Composite endpoint that includes the incidence specified infections:
- Length of hospital stay
- The usage of antibiotics required for treatment of a diagnosed infection
- The incidence of adverse effects
|
124 |
All |
18 Years and older (Adult, Older Adult) |
NCT02837939 |
IMUNO - HEGITO 7 |
IMUNO-HEGITO7 |
July 2016 |
July 2020 |
July 2020 |
July 20, 2016 |
September 20, 2017 |
|
- F.D.Roosevelt Teaching Hospital with policlinic Banska Bystrica
Banska Bystrica, Slovakia
|
|
| 14 |
NCT02835781 |
Completed |
Acellular Dermal Matrix in Breast Reconstruction |
|
- Other: Acellular dermal matrix implantation
|
Observational
|
|
- University Hospital Bratislava
- Comenius University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of complications in patients receiving acellular dermal matrix evaluated at 6 months after primary implantation
- Histologic evaluation of ADM implants upon planned explantations
- Satisfaction with breast reconstruction outcome evaluated by Breast-Q questionnaire
|
30 |
Female |
18 Years to 60 Years (Adult) |
NCT02835781 |
UHB/006/2015/MB |
Adermbrerec |
January 2010 |
January 2014 |
June 2016 |
July 18, 2016 |
July 18, 2016 |
|
- University Hospital Bratislava
Bratislava, Slovakia
|
|
| 15 |
NCT02819960 |
Recruiting |
Prevention of Irinotecan Induced Diarrhea by Probiotics |
|
- Drug: PROBIO-FIX INUM®
- Drug: Placebo
|
Interventional
|
Phase 3 |
- S&D Pharma SK s.r.o.
- National Cancer Institute, Slovakia
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Prevention of grade 3-4 diarrhea induced by irinotecan based chemotherapy
- Progression-free survival
- Prevention of any grade of diarrhea
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02819960 |
2 |
|
March 2016 |
July 2020 |
December 2020 |
June 30, 2016 |
January 17, 2019 |
|
- National Cancer Institute
Bratislava, Slovakia
|
|
| 16 |
NCT02769559 |
Completed |
Reduction Mammaplasty and Improved Quality of Life |
- Macromastia
- Signs and Symptoms
- Quality of Life
|
- Procedure: Reduction mammaplasty
|
Observational
|
|
- University Hospital Bratislava
- Comenius University
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Quality of life
- Rate of adverse outcomes
|
52 |
Female |
18 Years to 63 Years (Adult) |
NCT02769559 |
UHB/005/2015/MB |
MammaRed |
January 2000 |
December 2014 |
May 2016 |
May 11, 2016 |
May 12, 2016 |
|
- University Hospital Bratislava
Bratislava, Slovakia
|
|
| 17 |
NCT02742311 |
Recruiting |
EuroPainClinics® Study V (Prospective Observational Study) |
- Back Pain
- Intervertebral Disc Herniation
|
- Procedure: Endoscopic disectomy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1.Pain as assessed by the Visual analogue scale All acquired information will be noted in to the special anonymous protocol
- 2.Pain localization as assessed by note of radiating dermatome as neurologic examination
- 3.Pain progress as assessed by global pain scale
- 4. Changes in analgesics drugs consumption as assessed by equianalgesic dose ratios for opioids
|
500 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02742311 |
EK: 9N-2015 |
EPCSV |
January 2016 |
May 2018 |
January 2019 |
April 19, 2016 |
July 31, 2018 |
|
- Europainclinics algesiology ambulance
Bardejov, Slovakia
|
|
| 18 |
NCT02693769 |
Terminated |
A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils |
- ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)
|
- Drug: fluticasone propionate/formoterol fumarate breath actuated inhaler
- Drug: Indacaterol maleate / glycopyrronium bromide capsules
|
Interventional
|
Phase 2
Phase 3 |
- Mundipharma Research Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.) versus Ultibro Breezhaler 85/43 µg (1 puff o.d.) in terms of the percentage of eosinophils in induced sputum
- The efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.) versus Ultibro Breezhaler 85/43 µg (1 puff o.d.) in terms of the serum concentration of surfactant protein D (SPD)
|
2 |
All |
40 Years and older (Adult, Older Adult) |
NCT02693769 |
KFL3503 |
|
July 2016 |
October 2016 |
December 2016 |
February 29, 2016 |
December 12, 2016 |
|
- JURMED, s.r.o.
Košice, Slovakia
|
|
| 19 |
NCT02544685 |
Active, not recruiting |
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients |
- Febrile Neutropenia
- Neutropenia
- Infection in an Immunocompromised Host
- Cancer
|
- Dietary Supplement: Probio-Fix Inum
- Dietary Supplement: Beneo Synergy 1
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Reduction in the incidence of febrile neutropenia episodes
- Safety evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
- Reduction of the total duration of febrile neutropenia
- (and 4 more...)
|
120 |
All |
6 Months to 19 Years (Child, Adult) |
NCT02544685 |
1 |
FENSY |
July 2010 |
September 2019 |
October 2019 |
September 9, 2015 |
January 17, 2019 |
|
- University Children's Hospital Banska Bystrica
Banska Bystrica, Slovakia
|
|
| 20 |
NCT02414685 |
Recruiting |
First Line TIP in Poor Prognosis TGCTs. |
|
- Drug: Paclitaxel
- Drug: Ifosfamide
- Drug: Cisplatin
|
Interventional
|
Phase 2 |
- National Cancer Institute, Slovakia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response rate
- Response rate
- Progression-free survival
- (and 2 more...)
|
37 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02414685 |
GCTSK003 |
TIP |
April 2015 |
December 2019 |
December 2019 |
April 13, 2015 |
January 4, 2018 |
|
- National Cancer Institute
Bratislava, Slovakia
|
|
| 21 |
NCT02351050 |
Completed |
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting |
|
- Device: Sonolysis
- Other: Sham procedure
|
Interventional
|
Not Applicable |
- University Hospital Ostrava
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- New infarction
- Cognitive functions changes, measured by ADAS, MMSE, Clock Drawing Test and Verbal Fluency Test
- Large new infarction, infarction ≥0.5 mL detected using magnetic resonance diffusion weighted images (MRI-DWI)
- (and 3 more...)
|
144 |
All |
35 Years to 90 Years (Adult, Older Adult) |
NCT02351050 |
13595 |
|
April 2015 |
September 2017 |
November 2017 |
January 30, 2015 |
March 26, 2018 |
|
- University Hospital Nitra
Nitra, Slovakia
|
|
| 22 |
NCT02325804 |
Unknown † |
Effect of Specific Diet and Physical Activity on Weight and/or Fat Loss |
|
- Behavioral: Lifestyle Counseling
|
Interventional
|
Not Applicable |
- Slovak Academy of Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- A Body weight change after specific weight loss intervention
- Metabolic parameters
|
60 |
All |
18 Years to 50 Years (Adult) |
NCT02325804 |
FEXE- 11/2014 |
|
December 2014 |
December 2016 |
December 2017 |
December 25, 2014 |
April 27, 2016 |
|
- Biomedical Center, Slovak Academy of Sciences, Institute of clinical and translational reasearch
Bratislava, Slovakia
|
|
| 23 |
NCT02216370 |
Unknown † |
Detection of Occult Paroxysmal AF in Cryptogenic Stroke or TIA Patients Using an Implantable Loop Recorder and Correlation With Genetic Markers. |
- Cryptogenic Stroke or TIA
- Atrial Fibrillation
|
|
Observational
|
|
- University Hospital, Martin
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Documented Atrial Fibrillation after episode of cryptogenic stroke / TIA Documented genetic mutation PITX2 and ZFHX3
- Time to documented Atrial Fibrillation Reccurent stroke or TIA Stroke Secondary Prevention Therapy changes within 12 months Neuroimaging Changes ( brain CT/ MRI)
|
125 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02216370 |
NRRXT0001 |
|
April 2014 |
June 2018 |
June 2018 |
August 13, 2014 |
August 13, 2014 |
|
- Faculty Hospital Nitra
Nitra, Slovakia
|
|
| 24 |
NCT02055612 |
Completed |
Mobile Clinic - a Cross-sectional Epidemiological Survey |
- Age Related Macular Degeneration
|
|
Observational
|
|
- Novartis Slovakia, s.r.o.
- Novartis
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Aged specific prevalence of aged-related macular degeneration
- Social-demography structure of patients with wAMD
- Risk factors associated with wAMD (e.g. co-morbidities, nutrition effects)
- (and 2 more...)
|
3278 |
All |
55 Years and older (Adult, Older Adult) |
NCT02055612 |
CRFB002ASK01 EPI |
|
March 2013 |
May 2013 |
July 2013 |
February 5, 2014 |
March 1, 2017 |
|
- Novartis Slovakia, s.r.o.
Bratislava, Slovakia
|
|
| 25 |
NCT02026856 |
Completed |
Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis |
|
- Drug: sodium selenite pentahydrate
- Other: placebo - continuous saline NaCl 50 ml
|
Observational
|
|
- Pavol Jozef Safarik University
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- mortality
- The oxygenation index
|
4 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT02026856 |
Se-AOX 109/2011 |
Se-AOX |
December 2013 |
December 2013 |
December 2013 |
January 3, 2014 |
April 10, 2017 |
|
- 1st clinic of anesthesiology and intesive care, University hospital of Louis Pasteur
Košice, Slovakia
|
|
| 26 |
NCT02023398 |
Completed |
BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction |
- Circumferential Reduction
- Waist Circumferential Reduction
|
- Device: BTL-9000 HFT
- Device: sham BTL-9000 HFT
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Waist Circumference Reduction
- Adverse Events
|
102 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02023398 |
BTL-9000 HFT |
|
September 2013 |
December 2013 |
December 2013 |
December 30, 2013 |
September 19, 2014 |
|
- Polyklinika Mytna
Bratislava, Slovakia
|
|
| 27 |
NCT01862978 |
Unknown † |
Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke |
|
- Drug: Heparin
- Drug: Nadroparin
- Drug: Placebo
|
Interventional
|
Phase 4 |
- University Hospital, Martin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety of nadroparine or heparin
- Efficacy of nadroparine or heparin
|
150 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01862978 |
MTSVKNEUROL001 |
Heparinas |
May 2013 |
May 2015 |
December 2015 |
May 27, 2013 |
August 15, 2013 |
|
- Neurology Clinic Univeristy Hospital in Martin
Martin, Slovakia
|
|
| 28 |
NCT01800981 |
Unknown † |
Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care |
- Burns, Upper Extremity
- Burns, Lower Extremity
|
|
Observational
|
|
|
Industry |
- Time Perspective: Prospective
|
- Functionality evaluation using self reported questionnaires and ROM measurements
|
53 |
All |
10 Years to 61 Years (Child, Adult) |
NCT01800981 |
MW2012-12-12 |
|
March 2013 |
July 2013 |
|
February 28, 2013 |
February 28, 2013 |
|
- Clinic of Burns and reconstructive surgery hospital
Kosice, Slovakia
|
|
| 29 |
NCT01788098 |
Completed |
Genetics and Mechanisms of Rheumatoid Arthritis |
- Rheumatoid Arthritis
- Leukocytes, Mononuclear
- Genetic Association Studies
|
|
Observational
|
|
- Slovak Academy of Sciences
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Genetic association
- Peripheral blood mononuclear cells reactivity
|
790 |
All |
18 Years and older (Adult, Older Adult) |
NCT01788098 |
RASGENAS
ATMOS N00024 |
RASGENAS |
October 2009 |
June 2012 |
December 2012 |
February 11, 2013 |
February 11, 2013 |
|
- Slovak Academy of Sciences, Center for Molecular Medicine
Bratislava, Slovakia
|
|
| 30 |
NCT01579461 |
Completed |
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects |
- Pharmacokinetics
- Healthy Subjects
- Mild and Moderate Hepatic Impairment
|
|
Interventional
|
Phase 1 |
- Astellas Pharma Europe B.V.
- Astellas Pharma Inc
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Assess the single dose pharmacokinetics of Mirabegron in healthy subjects compared to subjects with hepatic impairment
- Safety assessed by incidence of adverse events, lab tests, physical exam, ECG and vital signs
|
32 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01579461 |
178-CL-039
2008-000210-77 |
|
November 2008 |
April 2009 |
April 2009 |
April 18, 2012 |
September 5, 2013 |
|
- FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie
Bratislava, Slovakia
|
|
| 31 |
NCT01548248 |
Completed |
Efficacy and Safety of Levemir® Used as Basal Insulin |
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
|
- Drug: insulin detemir
- Drug: insulin aspart
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in HbA1c (glycosylated haemoglobin)
- Change in weight
- Change in fasting plasma glucose (FPG)
- (and 4 more...)
|
631 |
All |
Child, Adult, Older Adult |
NCT01548248 |
NN304-1928 |
|
January 2006 |
October 2006 |
October 2006 |
March 8, 2012 |
January 31, 2017 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 32 |
NCT01542489 |
Completed |
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos |
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
|
- Drug: insulin detemir
- Drug: insulin aspart
- Drug: human soluble insulin
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in HbA1c (glycosylated haemoglobin)
- Change in 7-point blood glucose variability
- Change in body weight
- (and 4 more...)
|
480 |
All |
Child, Adult, Older Adult |
NCT01542489 |
NN304-1927 |
|
October 2006 |
April 2007 |
April 2007 |
March 2, 2012 |
January 31, 2017 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 33 |
NCT01536639 |
Completed |
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes |
- Diabetes
- Diabetes Mellitus, Type 2
|
- Drug: biphasic insulin aspart 30
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- HbA1c (glycosylated haemoglobin)
- Fasting plasma glucose (FPG)
- Post−prandial glucose (PPG)
- (and 3 more...)
|
454 |
All |
Child, Adult, Older Adult |
NCT01536639 |
BIASP-1929 |
|
January 2006 |
December 2006 |
December 2006 |
February 22, 2012 |
January 9, 2017 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 34 |
NCT01516242 |
Completed |
Evaluation of Safety and Parameters of Application Technique |
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Delivery Systems
|
- Other: No treatment given
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of insulin applications (punctures)
- Reasons leading to change of the therapy
- Patient satisfaction with NovoPen® 4 insulin delivery system
- (and 2 more...)
|
4819 |
All |
Child, Adult, Older Adult |
NCT01516242 |
MS236-1926 |
|
October 2006 |
December 2007 |
December 2007 |
January 24, 2012 |
November 7, 2016 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 35 |
NCT01466231 |
Completed |
Everolimus in Refractory Testicular Germ Cell Cancer |
|
|
Interventional
|
Phase 2 |
- National Cancer Institute, Slovakia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Favorable response rate
- Clinical benefit rate
- (and 5 more...)
|
15 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01466231 |
GCTSK002 |
|
November 2011 |
June 2015 |
June 2015 |
November 7, 2011 |
January 12, 2016 |
|
- National Cancer Institute
Bratislava, Slovakia
|
|
| 36 |
NCT01449500 |
Unknown † |
Supplementation With L. Reuteri in H. Pylori Infected Adults |
- Dyspepsia
- H. Pylori Infection
|
- Dietary Supplement: L. reuteri
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Lama Medical Care s.r.o.
- BioGaia AB
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Increase in the number of subjects with treatment success after 28 days of treatment with omeprazole + L. reuteri compared to those given omeprazole + placebo.
- Fewer patients in the L. reuteri treatment success group with demonstrated presence of H. pylori infection, measured as UBT on Day 90 compared to the placebo treatment success group
|
56 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01449500 |
CSUB0028 |
|
October 2011 |
April 2012 |
April 2012 |
October 10, 2011 |
October 10, 2011 |
|
- Gastroenterology Hepatology Centrum THALION, Poliklinika Mytna - 2.poscodie Mytna ul. 5
Bratislava, Slovakia
|
|
| 37 |
NCT01444833 |
Unknown † |
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker |
|
|
Interventional
|
Not Applicable |
- Slovak Academy of Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Systemic Insulin Sensitivity after Replacement of ACE Inhibitor by AT1 Blocker
- Adipocyte Diameter from Subcutaneous Adipose Tissue after Replacement ACE Inhibitor by AT1 Blocker
|
35 |
Male |
25 Years to 50 Years (Adult) |
NCT01444833 |
MinHealth
2007/27-SAV-02 |
ADIRAS |
October 2008 |
March 2009 |
December 2012 |
October 3, 2011 |
October 3, 2011 |
|
- Institute of Experimental Endocrinology, SAS
Bratislava, Slovakia
|
|
| 38 |
NCT01405599 |
Completed |
Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects |
- Digestive System Disorders
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cmax of ulimorelin
- AUC of ulimorelin
|
32 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01405599 |
NPJ5004-01/2011 (HEP) |
|
June 2011 |
October 2011 |
October 2011 |
July 29, 2011 |
October 16, 2012 |
|
- Univerzitna nemocnica Bratislava, nem.
Bratislava, Slovakia
|
|
| 39 |
NCT01400984 |
Completed |
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia |
|
|
Observational
|
|
- Merck KGaA, Darmstadt, Germany
- Merck spol. s r.o., Slovakia
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Mean percent of daily recorded adherence
- Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod™
- Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment
- Correlation of adherence with current IGF-1 status (i.e. above, below or within normal ranges)
|
92 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01400984 |
EMR200104-526 |
ECOS SVK |
December 31, 2011 |
December 31, 2015 |
December 31, 2015 |
July 25, 2011 |
December 26, 2017 |
|
- For Recruiting Locations in Slovakia
Please Contact The Merck KGaA Communication Center, Slovakia
|
|
| 40 |
NCT01350700 |
Completed |
Long Term Follow up of Scars Formation and Quality of Life Assessment Study |
- Scars Formation
- Quality of Life
|
- Other: Scars assessment & QOL
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- 1. Scar assessment of target wounds that have been treated by Debrase or SOC during MW2004-11-02 using Modified Vancouver Scar Scale (MVSS)
- 2. To evaluate and compare the Quality of Life (QoL) in adult and children that their burn wounds were treated with Debrase or SOC in study MW2004-11-02
|
148 |
All |
4 Years to 55 Years (Child, Adult) |
NCT01350700 |
MW2012-01-02 |
|
June 2011 |
November 2011 |
November 22, 2011 |
May 10, 2011 |
November 1, 2017 |
|
- Clinic of Burns and reconstructive surgery hospital
Kosice, Slovakia
|
|
| 41 |
NCT01217879 |
Completed |
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia |
|
- Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough
- Number of Participants with Adverse Events among patients, who had to stop their previous ACE-I treatment due to cough
|
980 |
All |
18 Years and older (Adult, Older Adult) |
NCT01217879 |
15379
KL0910SK
14881 - KL0910PL
GM.2009-04-06.0017 |
COUGH |
January 2010 |
September 2010 |
September 2010 |
October 8, 2010 |
November 16, 2012 |
|
|
|
| 42 |
NCT01010503 |
Completed
Has Results |
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis. |
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Adherent to Original Treatment
- Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason
- Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason
- (and 12 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT01010503 |
ML22508
2009-011520-53 |
|
June 2009 |
May 2010 |
May 2010 |
November 10, 2009 |
August 13, 2014 |
August 13, 2014 |
|
|
| 43 |
NCT00976326 |
Completed |
A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area under the NN1250 concentration-time curve after single-dose
- Maximum observed NN1250 concentration after single-dose
- Renal clearance of NN1250
- Number of adverse events
|
12 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00976326 |
NN1250-1989
2009-009465-34 |
|
August 2009 |
March 2010 |
March 2010 |
September 14, 2009 |
January 20, 2017 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 44 |
NCT00872066 |
Completed |
A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement |
- Rheumatoid Arthritis
- Osteoarthritis
- Post-traumatic Arthritis
- (and 6 more...)
|
- Device: SmartSet® HV bone cement
- Device: SmartSet® GHV bone cement
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Kaplan-Meier survivorship
- Harris Hip Score
- Oxford Hip Score
- Radiological Analysis
|
243 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00872066 |
CT02/11 |
|
March 2006 |
July 2016 |
July 2016 |
March 31, 2009 |
March 3, 2017 |
|
- Orthopaedic-traumatology Clinic University Hospital Martin
Martin, Slovakia
|
|
| 45 |
NCT00687284 |
Completed |
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus |
- Diabetes
- Diabetes Mellitus, Type 2
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Change in glycaemic control as measured by HbA1c.
- Percentage of subjects to reach HbA1c below 7.0% and below or equal 6.5%
- The effect on glycaemic control as measured by FPG
- (and 2 more...)
|
2188 |
All |
Child, Adult, Older Adult |
NCT00687284 |
NN304-3515 |
START |
February 2008 |
June 2010 |
June 2010 |
May 30, 2008 |
October 28, 2016 |
|
- Novo Nordisk Investigational Site
Kosice, Slovakia
|
|
| 46 |
NCT00676741 |
Completed |
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin |
- Diabetes
- Diabetes Mellitus, Type 2
|
- Drug: insulin aspart
- Drug: biphasic insulin aspart 30
- Drug: insulin detemir
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Metabolic control measured as HbA1c
- Percentage of subjects achieving HbA1c below 7.0% and below or equal 6.5%
- Change in FPG (glucose variability)
- (and 6 more...)
|
3809 |
All |
18 Years and older (Adult, Older Adult) |
NCT00676741 |
BIASP-3516 |
COMMIT |
February 2008 |
May 2010 |
May 2010 |
May 13, 2008 |
October 31, 2016 |
|
- Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 47 |
NCT00635674 |
Completed |
Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome |
- Obstructive Sleep Apnea
- Metabolic Syndrome
|
- Device: CPAP device - REMstar Plus, Respironics, Murrysville, USA
|
Interventional
|
Not Applicable |
- Pavol Jozef Safarik University
|
Other |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cardiovascular disease risk profile (as assessed using the multivariable risk factor algorithm)
- insulin sensitivity
|
32 |
All |
35 Years to 75 Years (Adult, Older Adult) |
NCT00635674 |
OSAMSCPAP |
|
February 2007 |
February 2008 |
February 2008 |
March 14, 2008 |
March 14, 2008 |
|
- Medical Faculty, PJ Safarik University
Kosice, Slovakia
|
|
| 48 |
NCT00490711 |
Completed |
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer |
- Epithelial Ovarian Cancer
|
- Drug: gemcitabine
- Drug: carboplatin
- Drug: paclitaxel
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Progression-free survival
- 2-year survival
- (and 2 more...)
|
7 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT00490711 |
4720
B9E-MC-S205 |
|
July 2003 |
|
April 2005 |
June 25, 2007 |
June 25, 2007 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bratislava, Slovakia
|
|
| 49 |
NCT00315718 |
Completed |
Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2) |
- Diabetes Mellitus, Type 2
|
- Drug: Extract from Hintonia latiflora bark
|
Interventional
|
Phase 3 |
- Harras Pharma Curarina GmbH
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HbA1c values
- Postprandial blood glucose
- Fasting blood glucose
- (and 6 more...)
|
10 |
All |
45 Years to 80 Years (Adult, Older Adult) |
NCT00315718 |
HPC-02/1998 |
|
June 2002 |
|
June 2005 |
April 19, 2006 |
April 19, 2006 |
|
- Hospital of Trencin
Trencin, Slovakia
|
|
| 50 |
NCT00158769 |
Completed |
A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers |
|
- Drug: Intravenous GR270773 - Phospholipid emulsion
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare drug concentrations in the blood between patients with impaired liver function and normal healthy adults, after 72 hours. Determine whether administration of study drug alters the lipid make-up of healthy adults in any way.
- Determine drug concentrations in blood after 2 hour run-in period and after 72 hour infusion period. Determine whether administration of study drug alters the lipid make-up of patients with impaired liver function in any way.
|
16 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00158769 |
EMD10007 |
|
March 31, 2005 |
October 26, 2005 |
October 26, 2005 |
September 12, 2005 |
September 25, 2017 |
|
- GSK Investigational Site
Bratislava, Slovakia
|
|
| 51 |
NCT00130949 |
Completed |
ALGRX 4975 in the Treatment of Tennis Elbow |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Pain induced by resisted wrist dorsiflexion 4 weeks after treatment
- Pain induced by resisted wrist dorsiflexion (other than 4 weeks)
- Grip strength
- (and 6 more...)
|
45 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00130949 |
4975-2-005-2
Eudra CT No : 2004-001000-12 |
|
November 2004 |
|
November 2005 |
August 17, 2005 |
December 20, 2006 |
|
- Ortopedicko-Traumatologicka Klinika
Kosice, Slovakia
|
|
| 52 |
NCT03557398 |
Completed |
Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women |
|
- Device: Hydeal-D vaginal pessaries
|
Interventional
|
Not Applicable |
- Fidia Farmaceutici s.p.a.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of the average score of Vaginal Health Index (VHI)
- Change of vaginal pH
- Change of patient's perception of vulvovaginal symptoms
- (and 6 more...)
|
40 |
Female |
45 Years to 75 Years (Adult, Older Adult) |
NCT03557398 |
QQ53-17-01 |
|
November 29, 2017 |
May 29, 2018 |
May 29, 2018 |
June 15, 2018 |
June 15, 2018 |
|
- Gynkomed s.r.o.
Bratislava, Slovakia - ULMUS, s r.o.
Hlohovec, Slovakia
|
|
| 53 |
NCT02314598 |
Active, not recruiting |
Therapy Coil Electrogram Collection Study |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Occurrence of abnormal electrograms during a lead issue
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT02314598 |
TEC Study |
TEC |
January 2015 |
September 20, 2017 |
October 20, 2017 |
December 11, 2014 |
June 20, 2017 |
|
- SUSCCH
Banska Bystrica, Slovakia - NUSCH
Bratislava, Slovakia
|
|
| 54 |
NCT02253732 |
Completed |
Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs |
- Mild Cognitive Impairment
- Alzheimer Disease
- Parkinson Disease
- Healthy Volunteers
|
- Behavioral: 3 months exercise intervention program
|
Interventional
|
Not Applicable |
- Slovak Academy of Sciences
- University Hospital Bratislava
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- muscle microRNAs and myokines
- whole body energy metabolism
- cognitive function
- (and 2 more...)
|
30 |
All |
60 Years to 85 Years (Adult, Older Adult) |
NCT02253732 |
UEE-SAS |
Brain-Muscle |
September 2015 |
September 2017 |
March 2018 |
October 1, 2014 |
April 17, 2018 |
|
- Univeristy Hospital in Bratislava
Bratislava, Slovakia - Inst. Exp. Endocrinology Slovak Acad Sci
Bratislava, Slovakia
|
|
| 55 |
NCT02165826 |
Completed
Has Results |
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Drug: Roflumilast
- Drug: Roflumilast Placebo
- Drug: Standard of Care COPD Treatment
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason
- Percentage of Participants With Adverse Events of Interest
- Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period
- (and 15 more...)
|
1323 |
All |
40 Years and older (Adult, Older Adult) |
NCT02165826 |
RO-2455-302-RD
U1111-1150-2477
2013-001788-21 |
OPTIMIZE |
May 1, 2014 |
September 1, 2015 |
September 1, 2015 |
June 18, 2014 |
April 20, 2017 |
March 14, 2017 |
- Bardejov, Slovakia
- Spisska Nova Ves, Slovakia
|
|
| 56 |
NCT02011100 |
Completed |
Effect of Carnosine on Diabetes and Cardiovascular Risk Factors |
- Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease
|
- Dietary Supplement: Carnosine
|
Interventional
|
Not Applicable |
- Jozef Ukropec
- Slovak Academy of Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- oxidative stress
- chronic systemic inflammation
- level of glucose intolerance
|
28 |
All |
25 Years to 50 Years (Adult) |
NCT02011100 |
CarnoDMCVD |
Carnorisk |
December 2013 |
December 2017 |
March 2018 |
December 13, 2013 |
April 17, 2018 |
|
- Univeristy Hospital in Bratislava
Bratislava, Slovakia - Institute of Experimental Endocrinology Slovak Academy of Sciences
Bratislava, Slovakia
|
|
| 57 |
NCT00796718 |
Completed
Has Results |
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer |
|
- Radiation: Standard radiotherapy
- Drug: Capecitabine [Xeloda]
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Pathological Complete Response
- Percentage of Participants With Response to Treatment Assessed 4-6 Weeks After the Completion of Radiochemotherapy (Complete Response, Partial Remission or No Response to the Treatment)
- Percentage of Participants With Response to the Treatment Assessed 1 Month After Surgery (Complete Response, Partial Remission or No Response to the Treatment)
- Percentage of Participants With Adverse Events
|
62 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00796718 |
ML21800
2008-003980-38 |
|
October 2008 |
August 2010 |
August 2010 |
November 24, 2008 |
August 25, 2016 |
August 25, 2016 |
- Banska Bystrica, Slovakia
- Bratislava, Slovakia
|
|
| 58 |
NCT03440125 |
Completed |
Cayenne Pepper Cataplasm - Safety Study |
|
- Drug: Cayenne Pepper topical
- Device: Electrical stimulation
- Procedure: Massage
|
Interventional
|
Phase 1
Phase 2 |
- University of Primorska
- S2P, Science to Practice, Ltd.
- Comenius University
- (and 2 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in concentration of circulating biomarkers of inflammation, neudroendocrine stress and blood vessel activation
- Change in systolic and diastolic blood pressure
- Heart rate
- (and 7 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03440125 |
UP-MunariStudy |
Munari04 |
March 15, 2016 |
November 15, 2016 |
December 15, 2016 |
February 20, 2018 |
February 20, 2018 |
|
- Facultiy of Physical Education and Sports, Comenius University of Bratislava
Bratislava, Slovakia - Faculty of Health Sciences
Izola, Slovenia
|
|
| 59 |
NCT03277274 |
Completed |
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous (IV) TAK-954 |
- Hepatic Impairment
- Healthy Volunteers
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Cmax: Maximum Observed Plasma Concentration for TAK-954
- AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954
- AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954
- (and 5 more...)
|
26 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03277274 |
TAK-954-1006
2017-000714-37
U1111-1196-9190 |
|
November 9, 2017 |
September 1, 2018 |
September 10, 2018 |
September 11, 2017 |
September 14, 2018 |
|
- PRA CZ, s.r.o
Praha 7, Praha, Czechia - Summit Center of Clinical Research
Bratislava, Slovakia
|
|
| 60 |
NCT02705209 |
Completed |
Cayenne Pepper Cataplasm - Effect Study |
|
- Other: Cayenne Pepper Cataplasm
- Other: Placebo Cataplasm
|
Interventional
|
Not Applicable |
- Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation
- Comenius University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Two-point discrimination test
- Monofilament Test
- Skin Temperature
- (and 2 more...)
|
20 |
All |
50 Years to 65 Years (Adult, Older Adult) |
NCT02705209 |
Munari02 |
|
October 2015 |
December 2015 |
February 2016 |
March 10, 2016 |
March 10, 2016 |
|
- Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation
Vienna, Austria - Facultiy of Physical Education and Sports, Comenius University of Bratislava
Bratislava, Slovakia
|
|
| 61 |
NCT02621047 |
Completed
Has Results |
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Observed Plasma Concentration (Cmax) of Total Alectinib
- Cmax of Unbound Alectinib
- Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) for Total Alectinib
- (and 24 more...)
|
28 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02621047 |
NP29783
2015-002976-25 |
|
December 4, 2015 |
December 8, 2016 |
December 8, 2016 |
December 3, 2015 |
August 24, 2018 |
August 24, 2018 |
- Pharmaceutical Research Associates CZ, s.r.o.
Praha 7, Czechia - Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie
Bratislava, Slovakia
|
|
| 62 |
NCT01888393 |
Completed |
Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects |
- Hepatic Impairment
- Healthy
|
- Drug: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
|
Interventional
|
Phase 1 |
- Vertex Pharmaceuticals Incorporated
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Lumacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F
- Ivacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F
- Lumacaftor metabolites pharmacokinetic parameters, including Cmax and AUC
- (and 2 more...)
|
23 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01888393 |
VX13-809-010 |
|
June 2013 |
November 2013 |
November 2013 |
June 27, 2013 |
November 19, 2013 |
|
- Praha, Czech Republic
- Bratislava, Slovakia
|
|
| 63 |
NCT01679977 |
Completed |
Vibrational-proprioceptive Resistance Exercise Training Versus Neuromuscular Electrical Stimulation Training in Elderly People With Muscle Weakness |
- Muscle Weakness Condition
- Therapy Effect
|
- Device: Vibrational-proprioceptive Resistance Exercise Training
- Device: Neuromuscular Electrical Stimulation Training
|
Interventional
|
Not Applicable |
- Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation
- European Union
- Ministry of Science and Research, Austria
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum voluntary knee extension torque
|
150 |
All |
65 Years to 85 Years (Older Adult) |
NCT01679977 |
MOBIL |
MOBIL |
June 2008 |
December 2014 |
March 2015 |
September 6, 2012 |
March 7, 2016 |
|
- Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation
Vienna, Austria - Facultiy of Physical Education and Sports, Comenius University of Bratislava
Bratislava, Slovakia
|
|
| 64 |
NCT01577680 |
Completed |
A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: Inhaled GSK573719/vilanterol
- Drug: Inhaled GSK573719
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- GSK573719 and vilanterol pharmacokinetics
- GSK573719 pharmacokinetics
- Urine pharmacokinetics for GSK573719 (Treatment Period 1)
- (and 5 more...)
|
18 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01577680 |
114637 |
|
March 5, 2012 |
June 29, 2012 |
June 29, 2012 |
April 16, 2012 |
July 25, 2017 |
|
- GSK Investigational Site
Budapest, Hungary - GSK Investigational Site
Bratislava, Slovakia
|
|
| 65 |
NCT00932867 |
Completed |
Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment |
|
- Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment
|
3114 |
All |
18 Years and older (Adult, Older Adult) |
NCT00932867 |
14010
14010 - KL0711SK
14327 - KL0711RO |
SONAR |
December 2007 |
June 2008 |
August 2009 |
July 3, 2009 |
April 20, 2010 |
|
- Many Locations, Romania
- Many Location, Slovakia
|
|
| 66 |
NCT00653978 |
Unknown † |
Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures |
|
- Procedure: ERCP plus one biliary stent
- Procedure: ERCP plus two biliary stents
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Early complications
- 30-day mortality
- Late complications
- (and 2 more...)
|
150 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT00653978 |
Changhai-080129 |
|
May 2008 |
October 2011 |
December 2011 |
April 7, 2008 |
June 22, 2011 |
|
- Changhai Hospital, Second Military Medical University
Shanghai, China - Department of Surgery and Transplant Center
Astrova, Slovakia
|
|
| 67 |
NCT00470886 |
Completed |
Assessment of Compliance With Antihypertensive Telmisartan Therapy |
|
- Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
|
Observational
|
|
- Bayer
- Bang & Olufsen Medicom
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Efficacy and safety of the treatment with telmisartan reported by the physician with regard to usage the HelpingHand device
- Compliance with the treatment calculated on the basis of by HelpingHand and patients questionnaires
|
3400 |
All |
18 Years and older (Adult, Older Adult) |
NCT00470886 |
12827
KL0710PL
14237 - KL0710SK |
COAST |
April 2007 |
January 2010 |
January 2010 |
May 8, 2007 |
November 16, 2012 |
|
- Many Locations, Poland
- Many Locations, Slovakia
|
|
| 68 |
NCT01616095 |
Completed |
Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype |
- Growth Hormone Deficiency
|
|
Observational
|
|
- Slovak Academy of Sciences
- PFIZER, Bratislava, Slovakia
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Effects of GH therapy to GHD adults - the whole body level
- GH therapy effects on the endocrine, metabolic & inflammatory properties of adipose tissue
- comparison of GHD & control population
- Identification of the adiposity-associated parameters
|
44 |
All |
21 Years to 50 Years (Adult) |
NCT01616095 |
GH GIIR - 2011 |
GHAT |
April 2011 |
May 2013 |
August 2015 |
June 11, 2012 |
April 17, 2018 |
|
- V th Internal Clinic, Univeristy Hospital Bratislava, Comenius University
Bratislava, Slovakia - Inst. Exp. Endocrinology Slovak Acad Sci
Bratislava, Slovakia - National Institute of Endocrinology and Diabetology
Lubochna, Slovakia
|
|
| 69 |
NCT03330470 |
Recruiting |
Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease |
- Subjective Cognitive Impairment
- Mild Cognitive Impairment
- Parkinson Disease
- Healthy Volunteers
|
- Behavioral: exercise
- Dietary Supplement: carnosine supplementation
- Behavioral: stretching
- Dietary Supplement: supplementation with placebo
|
Interventional
|
Not Applicable |
- Slovak Academy of Sciences
- Comenius University
- University Hospital Bratislava
- National Cheng Kung University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- glucose tolerance
- learning/working memory
- motoric functions - Berg Balance Scale
- (and 2 more...)
|
100 |
All |
55 Years to 80 Years (Adult, Older Adult) |
NCT03330470 |
15-0253 |
|
January 1, 2017 |
December 31, 2020 |
December 31, 2020 |
November 6, 2017 |
September 17, 2018 |
|
- University Hospital Bratislava, Comenius University
Bratislava, Slovakia - Biomedical Research Center, Slovak Academy of Sciences
Bratislava, Slovakia - Laboratory of Cognitive Neurophysiology, Institute of Physical Education, Health & Leisure Studies, National Cheng Kung University
Tainan City, Tainan, Taiwan
|
|
| 70 |
NCT01388309 |
Completed |
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Disease activity score (DAS28)
- DAS 28 (subgroup on monotherapy)
- DAS 28 (subgroup on 4 mg/kg dose)
- Safety: Incidence of adverse events
|
64 |
All |
18 Years and older (Adult, Older Adult) |
NCT01388309 |
ML25524 |
|
July 2011 |
March 2013 |
March 2013 |
July 6, 2011 |
November 2, 2016 |
|
- Banska Bystrica, Slovakia
- Bratislava, Slovakia
- Kosice, Slovakia
- Piestany, Slovakia
|
|
| 71 |
NCT03664544 |
Recruiting |
PK Study in Subjects With Severe Hepatic Impairment |
- Severe Hepatic Impairment
- Healthy
|
|
Interventional
|
Phase 1 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Pharmacokinetic parameters of MCI-186: Peak drug concentration (Cmax)
- Pharmacokinetic parameters of MCI-186: Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)
- Pharmacokinetic parameters of MCI-186: Area under the concentration-time curve from time zero to infinity (AUC0-∞)
- (and 10 more...)
|
12 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03664544 |
MCI-186-E05
2018-001163-23 |
MCI-186-E05 HP |
November 6, 2018 |
December 2019 |
December 2019 |
September 10, 2018 |
November 19, 2018 |
|
- Investigational Centre
Prague, Czechia - Investigational Centre
Miskolc, Hungary - Investigational Centre
Bratislava, Slovakia
|
|
| 72 |
NCT00169507 |
Completed |
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23) |
- Prophylaxis Pneumococcal Vaccine
|
- Biological: Pneumococcal (vaccine)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Antibody concentrations (ELISA) to pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F 10-15 days after the single dose of Aventis Pasteur's 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).
- Before Pneumo 23 administration: Antibody concentrations (ELISA) to pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F & seropositivity (S+) status* (>= 0.05 µg/mL) * also measured 10-15 days after dose of Pneumo 23
- Before and 10-15 days after dose of Pneumo 23: Antibody titers (opsono) to selected pneumococcal serotypes and S+ status (>= 8)
- Occurrence of SAEs during study period
|
100 |
All |
31 Months to 57 Months (Child) |
NCT00169507 |
104083 |
|
March 2005 |
April 2005 |
April 2005 |
September 15, 2005 |
May 30, 2017 |
|
- GSK Investigational Site
Dubnica Nad Vahom, Slovakia - GSK Investigational Site
Nova Dubnica, Slovakia - GSK Investigational Site
Povazska Bystrica, Slovakia - GSK Investigational Site
Puchov, Slovakia
|
|
| 73 |
NCT03207425 |
Completed |
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cmax of EDP 305
- AUCinf of EDP 305
- t1/2 of EDP 305
- (and 2 more...)
|
29 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03207425 |
EDP 305-003 |
|
June 14, 2017 |
September 16, 2017 |
September 19, 2017 |
July 2, 2017 |
November 6, 2017 |
|
- American Research Corporation at The Texas Liver Institute
San Antonio, Texas, United States - Pharmaceuticals Research Associates
Prague, Czechia - Summit SRO
Bratislava, Slovakia
|
|
| 74 |
NCT01110967 |
Completed
Has Results |
Satellite™ PEEK Nucleus Replacement Retrospective Analysis |
- Degenerative Disc Disease, Lumbar
- Disc Herniation, Lumbar
|
|
Observational
|
|
- Medtronic Spinal and Biologics
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Health-related Quality of Life Using the Visual Analogue Scale for Back Pain
- Health-related Quality of Life Using the Visual Analogue Scale for Leg Pain
- Physical Functioning Using the Oswestry Disability Index (ODI)
- (and 5 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT01110967 |
Satellite Retrospective |
|
April 2010 |
October 2011 |
October 2011 |
April 27, 2010 |
January 28, 2016 |
August 7, 2014 |
- Masaryk Hospital
Usti nad Labem, Czech Republic - ÚVN SNP
Ružomberok, Slovakia - Instituto de Columna de Caracas
Caracas, Venezuela
|
|
| 75 |
NCT02203448 |
Completed |
Facet Wedge Post Market Study |
- Chronic Low Back Pain
- Degenerative Disc Disease
- Facet Joint Disease
- Pseudo Arthrosis Post Anterior Instrumentation
|
- Device: Facet Wedge spinal system
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- reoperation rate at the index level(s)
- the radiographic range of motion (ROM) at the index levels
- patient (back and leg) pain reported on a Numeric Rating Scale (NRS)
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02203448 |
CT13/01 |
|
May 1, 2014 |
August 31, 2018 |
August 31, 2018 |
July 30, 2014 |
October 19, 2018 |
|
- BG Unfallklinik
Frankfurt am Main, Germany - Schon Klinik Munchen
Munchen, Germany - UVN
Ruzomberok, Slovakia
|
|
| 76 |
NCT02021461 |
Completed
Has Results |
Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours |
|
- Drug: ESL Banana taste
- Drug: ESL Grape taste
- Drug: ESL Tutti-Frutti taste
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- Assessment of Taste Preference
|
38 |
All |
5 Years to 8 Years (Child) |
NCT02021461 |
BIA-2093-212 |
|
December 2012 |
December 2012 |
December 2012 |
December 27, 2013 |
April 3, 2014 |
April 3, 2014 |
- Dr. Bacos Cosma Medical Centre
Timisoara, Timis County, Romania - Psychiatry Clinical Hospital "Prof. Dr. Alexandru Obregia" - Department of Pediatric
Bucharest, Romania - Neurology Outpatient Clinic for children and adults
Bardejov, Slovakia
|
|
| 77 |
NCT01984736 |
Completed |
EVP-6124 Hepatic Impairment Study |
|
- Drug: Experimental: EVP-6124
|
Interventional
|
Phase 1 |
- FORUM Pharmaceuticals Inc
- PRA Health Sciences
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.
- Safety and tolerability of oral EVP-6124 in subjects with mild, moderate and severe hepatic impairment and in subjects with normal hepatic function.
|
34 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01984736 |
EVP-6124-020
2012-004467-53 |
|
June 2013 |
December 2014 |
|
November 15, 2013 |
January 15, 2015 |
|
- Jankovcova 1569/2c, 17000 Praha 7, Czech Republic
- Ul. Seczkowa 20B/8, Warszawa, Mazowieckie, 02-793, Poland
- Bardosova 2/A 83101 Bratislava, Slovakia
|
|
| 78 |
NCT01509495 |
Terminated |
Impedance Measurements in Heart Failure Patients |
|
- Device: Akern BIA101 and Custom Device
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Impedance Measurement of Patients in Heart Failure, impedance change first to last measurement
- Accuracy of Respiratory rate determined by impedance measurements
- Correlation between hemodynamic (central venous or arterial pressure) and impedance measurements (optional)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT01509495 |
RAE00564 |
SIM-HF |
December 2011 |
May 2014 |
May 2014 |
January 13, 2012 |
July 4, 2014 |
|
- Nemocnice Na Homolce
Praha, Czech Republic - Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik I
Würzburg, Franken, Germany - NUSCH
Bratislava, Slovakia
|
|
| 79 |
NCT01289223 |
Terminated |
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. |
|
- Drug: Bendamustine IV
- Other: Treatment of Physicians Choice
|
Interventional
|
Phase 3 |
- Mundipharma Research Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall Response Rate
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT01289223 |
BDM3502
2010-022102-41 |
ROBIN |
February 2011 |
July 31, 2018 |
July 31, 2018 |
February 3, 2011 |
September 3, 2018 |
|
- Princess Alexandra Hospital
Brisbane, Queensland, Australia - Royal Adelaide Hospital
Adelaide, Australia - Dr Ludmila Demitrovicova
Bratislava, Slovakia
|
|
| 80 |
NCT01266941 |
Completed |
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment. |
|
- Drug: Inhaled FF 200mcg/GW642444M 25mcg
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Fluticasone furoate and GW642444 pharmacokinetics (AUC(0-t), AUC (0-8), Cmax, tmax) on Day 1 and 7 and AUC(0-24) and t½ on Day 7.
- Serum cortisol weighted mean over 24 hours on Days -1 and 7.
- Maximum heart rate over time period 0-4 hours on Day 7.
- (and 2 more...)
|
35 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01266941 |
111789 |
|
October 18, 2010 |
July 15, 2011 |
July 15, 2011 |
December 24, 2010 |
July 21, 2017 |
|
- GSK Investigational Site
Hradec Kralove, Czechia - GSK Investigational Site
Prague 7, Czechia - GSK Investigational Site
Bratislava, Slovakia
|
|
| 81 |
NCT01208285 |
Completed |
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects |
- In Development for Cystic Fibrosis
|
|
Interventional
|
Phase 1 |
- Vertex Pharmaceuticals Incorporated
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- VX-770 pharmacokinetic parameters
- VX-770 metabolites pharmacokinetic parameters
- Safety as measured by adverse events, clinical laboratory values, standard electrocardiograms (ECGs), and vital signs
|
24 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01208285 |
VX10-770-013 |
|
September 2010 |
December 2010 |
December 2010 |
September 23, 2010 |
January 12, 2011 |
|
- Hradec Králové, Czech Republic
- Praha, Czech Republic
- Bratislava, Slovakia
|
|
| 82 |
NCT00437606 |
Terminated |
A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment. |
- Diabetes Mellitus, Type 2
|
- Drug: GK Activator (2)
- Drug: Ethanol
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.
- tmax, AUC0-6, AUC0-last, t1/2, CL/F, Ac, CL for GK Activator (2) and M4. Cmin, Cmax, tmax and tmin of plasma glucose.
- AEs, laboratory parameters.
|
2 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00437606 |
NP20131 |
|
March 2007 |
June 2007 |
June 2007 |
February 21, 2007 |
August 24, 2016 |
|
- Berlin, Germany
- Kiel, Germany
- Bratislava, Slovakia
|
|
| 83 |
NCT03728764 |
Recruiting |
Growth and Safety of a Two-stage Feeding System in Preterm Infants |
|
- Other: Preterm infant formula
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Growth of preterm infants
- Other growth parameter at other time points
- Other growth parameter
- (and 4 more...)
|
74 |
All |
up to 5 Days (Child) |
NCT03728764 |
17.14.INF |
|
October 10, 2018 |
November 2019 |
March 2020 |
November 2, 2018 |
November 2, 2018 |
|
- University Hospital in Pilsen
Pilsen, Czechia - Children's University Hospital
Cracovia, Poland - University Hospital in Martin
Martin, Slovakia - Fakultná nemocnica s poliklinikou
Nové Zámky, Slovakia
|
|
| 84 |
NCT02210871 |
Completed |
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function |
- Diabetes
- Diabetes Mellitus, Type 2
- Hepatic Impaired
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area under the semaglutide plasma concentration-time curve
- Maximum observed semaglutide plasma concentration
- Number of treatment emergent adverse events (TEAEs)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02210871 |
NN9535-3651
U1111-1149-3924
2009-011673-33 |
|
August 7, 2014 |
June 3, 2015 |
June 3, 2015 |
August 7, 2014 |
December 21, 2017 |
|
- Novo Nordisk Investigational Site
Warszawa, Poland - Novo Nordisk Investigational Site
Wolomin, Poland - Novo Nordisk Investigational Site
Bratislava, Slovakia - Novo Nordisk Investigational Site
Bratislava, Slovakia
|
|
| 85 |
NCT02534311 |
Completed |
A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Average change from baseline in DAS28
- Percent of participants achieving clinical remission defined as a DAS28 <2.6
- Percentage of participants achieving a DAS28 >=3.2
- (and 6 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02534311 |
ML29712 |
|
October 13, 2015 |
December 1, 2015 |
December 1, 2015 |
August 27, 2015 |
February 28, 2018 |
|
- Banska Bystrica, Slovakia
- Bratislava, Slovakia
- Bratislava, Slovakia
- (and 2 more...)
|
|
| 86 |
NCT00792909 |
Completed
Has Results |
Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A |
- Infections, Streptococcal
|
- Biological: Pneumococcal conjugate vaccine GSK1024850A
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group
- Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Synflorix Group 1 and Synflorix Group 2
- Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off in the Synflorix™ Group 1 and Synflorix™ Group 2
- (and 20 more...)
|
172 |
All |
36 Months to 46 Months (Child) |
NCT00792909 |
111736 |
|
December 2, 2008 |
July 2, 2009 |
July 2, 2009 |
November 18, 2008 |
December 14, 2017 |
December 14, 2017 |
- GSK Investigational Site
Dlha nad Oravou, Slovakia - GSK Investigational Site
Dolny Kubin, Slovakia - GSK Investigational Site
Ruzomberok, Slovakia - (and 2 more...)
|
|
| 87 |
NCT03456349 |
Completed |
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care |
|
- Drug: HTL0018318
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Heptares Therapeutics Limited
- Allergan
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Treatment emergent adverse events (TEAEs), Safety and Tolerability
|
60 |
All |
55 Years to 85 Years (Adult, Older Adult) |
NCT03456349 |
HTL0018318-202
2017-000649-34 |
|
November 10, 2017 |
July 16, 2018 |
July 16, 2018 |
March 7, 2018 |
July 20, 2018 |
|
- Syneos
Prague, Czechia - Syneos
Warsaw, Poland - Syneos
Bratislava, Slovakia - Syneos
Barcelona, Spain
|
|
| 88 |
NCT01116089 |
Completed |
Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer |
|
- Drug: Bramitob® administered by PARI LC® PLUS nebulizer
- Drug: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
|
Interventional
|
Phase 1 |
- Chiesi Farmaceutici S.p.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma tobramycin pharmacokinetic parameters (Cmax and AUC0-t) after twice daily inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer
- Plasma tobramycin pharmacokinetic parameters (Cmax, tmax and AUC0-t) after inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer
- Sputum tobramycin pharmacokinetic parameters (Cmax, tmax and AUC0-t) after inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer
- (and 4 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT01116089 |
CCD-0908-PR-0029
2009-016780-11 |
|
July 2010 |
October 2011 |
October 2011 |
May 4, 2010 |
November 17, 2011 |
|
- University Hospital Brno Bohunice
Brno, Czech Republic - SMSI Institude of Cardiology
Chisinau, Moldova, Republic of - University hospital with Health Center
Banská Bystrica, Slovakia - (and 2 more...)
|
|
| 89 |
NCT03405636 |
Not yet recruiting |
Xeltis Pulmonary Valved Conduit Safety and Performance Study |
- Heart Defects, Congenital
|
- Device: Xeltis Pulmonary Valved Conduit
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival at 12 months follow up post implantation
- Freedom from device related death, intervention and/or reoperation at 12 months follow up
- Mean pressure gradient across the area of conduit implantation (RV to PA) of less than 40 mm Hg at 12 months follow up
- Pulmonary regurgitation of equal or less than moderate (≤40 %) at 12 months follow up
|
55 |
All |
up to 21 Years (Child, Adult) |
NCT03405636 |
XEL-CR-02 |
|
June 2018 |
October 2020 |
October 2024 |
January 23, 2018 |
May 23, 2018 |
|
- Gottsegen György Hungarian Institute of Cardiology, Paediatric Cardiac Centre
Budapest, Hungary - Institute Jantung Negara, National Heart Institute
Kuala Lumpur, Malaysia - University Children's Hospital of Cracow (UCH),
Krakow, Poland - Childrens Heart Centre Slovak Republic
Bratislava, Slovakia
|
|
| 90 |
NCT02515656 |
Completed
Has Results |
Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis |
|
- Drug: POLYGYNAX®
- Drug: GYNODAKTARIN®
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Laboratoire Innotech International
- International Clinical Trials Association
- Venn Life Sciences
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit
- Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary
- Number of Patients With Change in Vaginal Discharge Assessed by the Investigator
- (and 3 more...)
|
661 |
Female |
18 Years to 64 Years (Adult) |
NCT02515656 |
PGX 401-11
2014-001759-22 |
PRISM |
September 2015 |
August 2016 |
August 2016 |
August 5, 2015 |
January 21, 2019 |
January 21, 2019 |
- TURKOVA
Praha, Czechia - PERCEVAL
Lyon, France - MARICIC
Belgrade, Serbia - GATOVA
Martin, Slovakia
|
|
| 91 |
NCT00931827 |
Completed |
Acceptability of Long-term Progestin-only Contraception in Europe |
|
- Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
- Drug: Implanon (Etonogestrel)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Continuation rate
- Bleeding intensity, dysmenorrhea, and user satisfaction (questionnaires completed by patient)
- Cumulative discontinuation rate for unintended pregnancy, bleeding problems, other medical reasons, for non-medical reasons
- (and 2 more...)
|
436 |
Female |
20 Years to 35 Years (Adult) |
NCT00931827 |
14688
MA0801
14239
14177
14176
14016 |
|
January 2008 |
November 2011 |
November 2011 |
July 2, 2009 |
December 24, 2013 |
|
- Many Locations, France
- Many Locations, Ireland
- Many Locations, Slovakia
- Many Locations, United Kingdom
|
|
| 92 |
NCT01592500 |
Completed |
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children |
- Pediatric Growth Hormone Deficiency
|
- Drug: MOD-4023
- Drug: Somatropin
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annual Height Velocity
- Height velocity at 6 months
- Change in height Standard Deviation Score (SDS)
- IGF-1 serum levels
|
53 |
All |
3 Years to 11 Years (Child) |
NCT01592500 |
CP-4-004
2011-004553-60 |
|
February 2012 |
July 2015 |
July 2015 |
May 7, 2012 |
December 9, 2015 |
|
- Children's Hospital "P. A. Kyriakou"
Athens, Greece - Buda Children's Hospital
Budapest, Hungary - Heim Pal Children's Hospital
Budapest, Hungary - Children's University Hospital
Kosice, Slovakia
|
|
| 93 |
NCT01378715 |
Unknown † |
Rosuvastatin Pre-Treatment Influences the Risk of Coronary Intervention Study |
|
|
Interventional
|
Phase 3 |
- University Hospital, Motol
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- periprocedural myocardial infarction during percutaneous coronary intervention
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT01378715 |
EK-134/10 |
TIPS-3 |
June 2010 |
June 2012 |
August 2012 |
June 22, 2011 |
June 22, 2011 |
|
- 1st Medical Dept., Faculty of Medicine in Plzen, Charles University in Prague, University Hospital Plzen
Plzen, Czech Republic - Dpt. of Cardiology, 2nd Medical School of Charles Universty and University Hospital Motol
Prague, Czech Republic - Dpt. of Cardiology, Hospital Podlesi
Třinec, Czech Republic - Eastern Slovakia Institute of Cardiovascular Diseases
Kosice, Slovakia
|
|
| 94 |
NCT00471003 |
Completed |
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension |
|
- Drug: Pritor (Telmisartan , BAY68-9291)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Efficacy and safety of the treatment with telmisartan reported by the physician
- Changes in metabolic parameters in telmisartan treated patients
|
5448 |
All |
18 Years and older (Adult, Older Adult) |
NCT00471003 |
12729
KL0601PL
13929 - KL0601SI
12804 - KL0601SK
14326 - KL0601HR |
METABOLIC |
September 2006 |
November 2009 |
November 2009 |
May 8, 2007 |
January 20, 2010 |
|
- Many Locations, Croatia
- Many Locations, Poland
- Many Locations, Slovakia
- Many Locations, Slovenia
|
|
| 95 |
NCT00765947 |
Completed
Has Results |
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension |
- Essential Hypertension ( Mild to Moderate)
|
- Drug: Aliskiren
- Drug: Hydrochlorothiazide
- Drug: Amlodipine
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen
- Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped-care, Aliskiren-based Regimen by Patient Subgroups of Mild and Moderate Hypertensive Patients, and Non-diabetic and Diabetic Patients.
- Changes From Baseline to Week 24 in Mean Sitting Systolic Blood Pressure [msSBP] and Mean Sitting Diastolic Blood Pressure [msDBP]
- (and 2 more...)
|
256 |
All |
18 Years and older (Adult, Older Adult) |
NCT00765947 |
CSPP100A2360 |
|
September 2008 |
August 2009 |
August 2009 |
October 3, 2008 |
March 11, 2011 |
January 11, 2011 |
- Investigative Site
Paris, France - Investigative Site
Budapest, Hungary - Investigative Site
Bucharest, Romania - Investigative Site
Bratislava, Slovakia
|
|
| 96 |
NCT00196716 |
Completed
Has Results |
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease |
|
- Biological: Fabrazyme (agalsidase beta)
|
Interventional
|
Phase 2 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium
- Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium
- Estimated Glomerular Filtration Rate (eGFR)
- (and 2 more...)
|
21 |
Male |
16 Years and older (Child, Adult, Older Adult) |
NCT00196716 |
AGAL-017-01 |
|
June 2003 |
April 2006 |
March 2007 |
September 20, 2005 |
April 3, 2015 |
April 2, 2009 |
- II. interní klinika 1. LF UK
Praha 2, Czech Republic - Tartu University Clinics, Department of Internal Medicine
Tartu, Estonia - Klinika Chorob Metabolicznych, Instytut "Pomnik-Centrum Zdrowia Dziecka"
Warsaw, Poland - Detská fakultná nemocnica Kramáre I. Interná klinika
Bratislava 37, Slovakia
|
|
| 97 |
NCT03634748 |
Completed |
Thrombolysis in stRoke With Unknown onSet Based on noncontrasT CT |
|
|
Observational
|
|
- University Hospital Tuebingen
- St John of God Hospital, Vienna
|
Other |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
|
117 |
All |
18 Years and older (Adult, Older Adult) |
NCT03634748 |
TRUST CT |
TRUST CT |
September 1, 2017 |
December 31, 2018 |
December 31, 2018 |
August 16, 2018 |
February 4, 2019 |
|
- St. Johns Hospital Vienna
Vienna, Austria - University Hospital Tuebingen
Tuebingen, Germany - University Hospital Bratislava
Bratislava, Slovakia - (and 2 more...)
|
|
| 98 |
NCT01185873 |
Completed |
A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment |
|
- Drug: danoprevir
- Drug: ritonavir
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics (plasma concentration) of danoprevir in patients with hepatic impairment
- Safety and tolerability (incidence of adverse events) of danoprevir in patients with hepatic impairment
|
81 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01185873 |
NP25290
2010-020314-29 |
|
February 2011 |
December 2013 |
December 2013 |
August 20, 2010 |
November 2, 2016 |
|
- Lenexa, Kansas, United States
- Prague 8, Czech Republic
- Praha 7, Czech Republic
- (and 2 more...)
|
|
| 99 |
NCT00286819 |
Completed |
Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer |
|
- Drug: the FEC75 and 95 regimen
|
Interventional
|
Phase 2 |
- Central European Cooperative Oncology Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this randomized phase II is to determine the relative dose intensity (RDI) of six adjuvant cycles of FEC75 and FEC90 regimens given every 14 days with pegfilgrastim (Neulasta) support in subjects with early breast cancer.
- - Incidence of dose delays and dose reductions of planned chemotherapy due to neutropenic events
- -Toxicity and tolerability
- (and 2 more...)
|
50 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT00286819 |
CECOG/Breast.2.2.005 |
|
April 2005 |
|
September 2006 |
February 6, 2006 |
May 16, 2012 |
|
- AKH, Universitätsklinik für Innere Medizin 1
Vienna, Austria - Onkotherápiás Klinika,
Szeged, Hungary - Medical University of Gdansk, Dept. of Oncology and Radiotherapy
Gdansk, Poland - (and 2 more...)
|
|
| 100 |
NCT01410955 |
Completed |
Prevention of Irinotecan Induced Diarrhea by Probiotics |
|
- Dietary Supplement: Probiotic formula
- Dietary Supplement: Placebo
|
Interventional
|
Phase 3 |
- Monsea Ltd.
- Harmonium International Inc.
- Pharma Agency
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Prevention of grade 3-4 diarrhea by probiotics in patients treated by irinotecan based chemotherapy
- Prevention of any grade of diarrhea
- Number of patients with any grade 3 or 4 toxicity or SAE related toxicity.
- Number of patients with any grade gastrointestinal symptoms
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT01410955 |
900450001 |
|
December 2011 |
December 2013 |
January 2014 |
August 5, 2011 |
January 23, 2014 |
|
- St.James Hospital and Clinic
Bardejov, Slovakia - Oncologic Institute of St.Elisabeth OUSA
Bratislava, Slovakia - National Cancer Institute, Slovakia
Bratislava, Slovakia - (and 3 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: